Statutory Profit Doesn't Reflect How Good Veracyte's Earnings Are

💡 Veracyte's statutory profit underestimates its true earnings potential due to non-cash items.

The Federal Reserve delivered a hawkish surprise on Wednesday, signaling that interest rate cuts remain further away than markets had hoped. Veracyte's ($VCYT) recent earnings report is a prime example of this phenomenon.

Non-Cash Items Distort Statutory Profit

Veracyte's statutory profit, which includes non-cash items such as depreciation and amortization, doesn't accurately reflect the company's underlying earnings power. In its latest earnings report, Veracyte reported a net loss of $0.17 per share, but excluded $0.23 per share from non-cash items. This results in an adjusted net income of $0.06 per share, a much more accurate representation of the company's earnings.

Veracyte's Earnings Growth

Veracyte's earnings growth has been impressive, with revenue increasing by 24% year-over-year in the latest quarter. This growth is driven by the company's expanding customer base and increasing adoption of its non-invasive diagnostic tests. The company's non-invasive lung nodule test has been particularly successful, with revenue growing by 35% year-over-year.

Veracyte's Valuation

Despite its strong earnings growth, Veracyte's valuation remains attractive. The company's price-to-earnings ratio is 10.5, compared to the industry average of 20.5. This suggests that the market is not fully pricing in the company's growth potential, making it a compelling investment opportunity.

What It Means for Investors